Modified interfron alpha with reduced immunogenicity

本发明涉及尤其是用于对人施用的、特别是用于治疗的多肽。所述的多肽是经修饰的多肽,其中,所述的修饰使得上述多肽在施用于人体时引起免疫应答的倾向减弱。本发明特别涉及对人α干扰素,且特别是α2干扰素(IFNα2)的修饰,所述修饰导致产生的蛋白质在体内应用时基本无免疫原性或免疫原性低于任何未修饰的对应物。 The present invention relates to polypeptides to be administered especially to humans and in particular for therapeutic use. The polypeptides are modi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: F.J. CARR, G. CARTER, T. JONGS
Format: Patent
Sprache:chi ; eng
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:本发明涉及尤其是用于对人施用的、特别是用于治疗的多肽。所述的多肽是经修饰的多肽,其中,所述的修饰使得上述多肽在施用于人体时引起免疫应答的倾向减弱。本发明特别涉及对人α干扰素,且特别是α2干扰素(IFNα2)的修饰,所述修饰导致产生的蛋白质在体内应用时基本无免疫原性或免疫原性低于任何未修饰的对应物。 The present invention relates to polypeptides to be administered especially to humans and in particular for therapeutic use. The polypeptides are modified polypeptides whereby the modification results in a reduced propensity for the polypeptide to elicit an immune response upon administration to the human subject. The invention in particular to the modification of human interferon alpha and specifically interferon alpha 2(INFalpha2) to result in proteins that are substantially non-immunogenic or less immunogenic than any non-modified counterpart when use in vivo.